MetaVia Q2 net loss $5.3M ($0.90/sh); DA-1726 Phase 1 Part 3 all patients at highest doses; topline data Q4 2026

MetaVia Inc.

Net loss of $5.3M ($0.90 per share) for Q2 2026, compared to net loss of $4.0M ($2.87 per share) in Q2 2025.
Cash and cash equivalents of $12.6M as of June 30, 2026, up from $10.3M at Dec 31, 2025; expects cash to fund operations through 2026.
All active patients in Phase 1 Part 3 of DA-1726 reached highest planned doses of 48 mg and 64 mg; 16-week topline data expected Q4 2026.
Presented data at EASL and ADA showing up to 9.1% mean weight loss at 8 weeks on 48 mg dose, with no plateau.
Planning End-of-Phase 2 meeting with FDA for vanoglipel (DA-1241) in MASH during H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.